Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID trial of early ceftazidime-avibactam guided by rapid diagnostics versus standard care for severe Gram-negative hospital infections
2024-520067-13-00Phase 4Authorised
- Sponsor
- National University of Singapore
- Start
- Apr 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 4, randomised, open-label trial in bloodstream infection (BSI), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Early ceftazidime-avibactam via rapid diagnostics with Standard of care antibiotics and diagnostics (2 arms). Primary endpoint: Composite endpoint of all-cause mortality and/or no improvement in SOFA score at Day 14. Planned start Apr 2026; status: authorised.
02
Drugs
ceftazidime + avibactam
03
Conditions
bloodstream infection (BSI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2024-520067-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520067-13-00.